<DOC>
	<DOCNO>NCT02009527</DOCNO>
	<brief_summary>The present project design test hypothesis arginase contribute endothelial dysfunction induce ischemia-reperfusion patient coronary artery disease .</brief_summary>
	<brief_title>Arginase Inhibition Ischemia-reperfusion Injury</brief_title>
	<detailed_description>Background : Arginase compete nitric oxide synthase common substrate L-arginine . Up-regulation arginase coronary artery disease ( CAD ) diabetes mellitus may reduce nitric oxide bioavailability contribute endothelial dysfunction ischemia-reperfusion injury . Arginase inhibition reduces infarct size animal model . Therefore aim current study investigate arginase inhibition protect endothelial dysfunction induce ischemia-reperfusion patient CAD without type 2 diabetes . Methods : Male patient CAD ( n=12 ) CAD + type 2 diabetes ( n=12 ) , include cross-over study blind evaluation . Endothelium-dependent vasodilatation assess flow-mediated dilatation ( FMD ) radial artery 20 min ischemia-reperfusion intra-arterial infusion arginase inhibitor ( N-hydroxy-nor-L-arginine , 0.1 mg/min ) saline . Results : The forearm ischemia-reperfusion well tolerate . Endothelium-independent vasodilatation assess sublingual nitroglycerin . Ischemia-reperfusion decrease FMD patient CAD 12.7±5.2 % 7.9±4.0 % saline administration ( P &lt; 0.05 ) . N-hydroxy-nor-L-arginine administration prevent decrease FMD CAD group ( 10.3±4.3 % baseline vs. 11.5±3.6 % reperfusion ) . Ischemia-reperfusion significantly reduce FMD patient CAD + type 2 diabetes . However , FMD reperfusion high follow nor-NOHA follow saline administration group ( P &lt; 0.01 ) . Endothelium-independent vasodilatation differ occasion . Conclusions : Inhibition arginase protect endothelial dysfunction cause ischemia-reperfusion patient CAD . Arginase inhibition may thereby promise therapeutic strategy treatment ischemia-reperfusion injury .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Coronary artery disease Age &gt; 80 year , Myocardial infarction/unstable angina within 6 week prior study , Raynaud 's phenomenon , peripheral vasculopathies , arterial shunt vascular surgery study arm , Any concomitant disease condition may interfere possibility patient comply complete study protocol , Participant ongoing study , Unwillingness participate follow oral write information .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>